Humabs BioMed, subsidiary of Vir Biotechnology

We are thrilled to announce that the U.S. FDA has cleared our IND application and granted Fast Track designation for our investigational combination therapy, tobevibart and elebsiran, for the treatment of chronic #hepatitis delta infection. Learn more here: https://bit.ly/4eFyNx5 #hepatitisdelta #hepatitisD #hepD

We’re excited to welcome Ramy Farid, Ph.D., and Norbert Bischofberger, Ph.D. to our board of directors. Their tremendous expertise and strategic insights will be invaluable as we work towards our mission of powering the immune system to transform lives. Learn more about them at these links: https://lnkd.in/gYVgPkP7 (Ramy) https://lnkd.in/gyT62qhj (Norbert)

Our Executive Management Team spent a few days immersed in science with our colleagues at our research site in Bellinzona, Switzerland before heading to Milan for the #EASL Congress 2024. Our exceptional scientists in Bellinzona discovered and developed antibodies that have helped us transform the infectious disease landscape – from Ebola to COVID-19, with much more to come! Angie K. Aine Hanly Jason Franklyn Vanina de Verneuil Marianne D. De Backer, MSc, PhD, MBA Jennifer Towne Mark Eisner Jenny Gumm Ed.D. Brent Sabatini, CPA Corti Davide Carey Hwang, MD, PhD

We’re unveiling new safety and efficacy data from our #hepatitisdelta program in an investor call and oral presentation at #EASLCongress 2024. Check out the preliminary data and learn more about the potential of our investigational regimens to be a meaningful treatment for the most severe form of viral hepatitis: https://bit.ly/4aR3rk7

#VirBiotechnology is at #EASLCongress 2024. So proud of the progress we are making towards our goal of developing a treatment for the millions of people living with #heaptitisdelta worldwide. #HepCantWait

Last week at our #VirBiotechnology #HepatitisAwarenessMonth event, we collaborated with @SFHepBFree on a #hepatitis panel discussion. We learned so much – from navigating a #hepatitisB diagnosis to all the hurdles patients experience along the way. Patient voices are a powerful force that not only shed light on the realities of living with this devastating disease, but also continue to inspire our work as we pursue innovative treatment options, including a functional cure. #Patientsarewaiting

Today marks the beginning of National #HepatitisAwarenessMonth. As we reflect on the success of this year’s #WorldHepatitisSummit, we are grateful for the opportunity to have been a part of such an important event alongside The World Hepatitis Alliance. Our team on the ground in Portugal had the opportunity to connect with Summit attendees and gather first-hand knowledge around #HepatitisDelta to help raise awareness about the most severe form of viral hepatitis. Check out some of their responses!

The World Health Organization recently published its updated guidelines for the prevention, diagnosis, care and treatment of people with chronic hepatitis B infection. This includes recommended testing for #HepatitisDelta, which is a major step forward for patients, physicians and researchers within the hepatitis delta and B communities. People who are impacted by hepatitis B can also be co-infected with hepatitis delta, but availability of hepatitis delta testing has historically been limited. Hepatitis delta is the most severe form of viral hepatitis, and there is an unmet need for screening and testing hepatitis B patients for a hepatitis delta coinfection. #TeamVir is hopeful that these updated WHO guidelines will help bridge these patients from testing and diagnosis to getting access to the care and treatment that they desperately need. In the meantime, we’ll continue working towards our goal of developing a chronic therapy to address the significant hepatitis delta treatment gap and a potential functional cure for the millions of people living with chronic hepatitis B. Read the WHO’s updated hepatitis B guidelines: https://bit.ly/49xMxpO

Intervista a Filippo Riva su La Regione: “Polo biomedico a Bellinzona. Servono più spazi per crescere” Il 9 aprile La Regione ha intervistato Filippo Riva, Membro di Comitato di Farma industria ticino e direttore di Humabs BioMed SA, in merito al polo biomedico di Bellinzona. Di seguito l'articolo completo. #farmaindustriaticino #polobiomedico

We’re #VirProud to participate in the 2024 #WorldHepatitisSummit in Lisbon, Portugal. As we pursue our goal to develop a functional cure for the millions living with chronic hepatitis B and a meaningful treatment for chronic hepatitis delta, this important event serves as a critical milestone in our collective educational efforts towards achieving the WHO goal of eradicating viral #hepatitis by 2030. The summit fosters a unique environment for dedicated experts, organizations, and patients from around the world to unite, share, and shape the future of hepatitis management. We look forward to the discussions to come as we collectively pursue #HepatitisDelta awareness, research, and treatment strategies. We invite you to join us in this crucial conversation – in person or virtually. Let’s connect, learn and innovate together towards a Hepatitis-free world: https://bit.ly/3VHndKK. Together we can make a difference. See you there!